| Select | PubMed ID | Description |
| 8308186 | J Allergy Clin Immunol. 1994 Jan;93(1 Pt 1):93-9.
The production of interferon-gamma in response to a major peanut allergy, Ara h
II correlates with serum levels of IgE anti-Ara h II.
Dorion BJ(1), Burks AW, Harbeck R, Williams LW, Trumble A, Helm RM, Leung DY.
|
| 15575928 | Allergy. 2005 Jan;60(1):35-40.
Characterization of the T-cell epitopes of a major peanut allergen, Ara h 2.
Glaspole IN(1), de Leon MP, Rolland JM, O'Hehir RE.
|
| 16189800 | Mol Nutr Food Res. 2005 Oct;49(10):963-71.
Allergenic characteristics of a modified peanut allergen.
King N(1), Helm R, Stanley JS, Vieths S, Lüttkopf D, Hatahet L, Sampson H, Pons
L, Burks W, Bannon GA.
|
| 21093025 | J Allergy Clin Immunol. 2011 Mar;127(3):608-15.e1-5. doi:
1016/j.jaci.2010.09.027. Epub 2010 Nov 18.
Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a
peanut allergy therapeutic.
Prickett SR(1), Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE.
|
| 29885257 | Allergy. 2018 Oct;73(10):2080-2082. doi: 10.1111/all.13498. Epub 2018 Jul 2.
Major hazelnut and peanut allergens are potent in basophil activation and
cross-react at T-cell level.
Masthoff LJN(1), Pasmans SGMA(1), van Doorn H(1), den Hartog Jager CF(1),
Geneugelijk K(1), Knol EF(1)(2), Bruijnzeel-Koomen CAFM(1), Lidholm J(3), Knulst
AC(1), Hoffen E(1).
|
| 30414861 | J Allergy Clin Immunol. 2018 Nov 8. pii: S0091-6749(18)31581-1. doi:
1016/j.jaci.2018.10.039. [Epub ahead of print]
Engineering of structural variants of the major peanut allergens Ara h 2 and Ara
h 6 for allergen-specific immunotherapy.
Bublin M(1), Kostadinova M(1), Radauer C(1), Varga EM(2), Hafner C(3),
Schmidthaler K(4), Saidova A(4), Maleki SJ(5), Szépfalusi Z(4), Eiwegger T(6),
Breiteneder H(1).
|
